-
公开(公告)号：US20220356236A1
公开(公告)日：2022-11-10
申请号：US17809941
申请日：2022-06-30
Applicant: NOVARTIS AG
Inventor： Chad Eric BIGELOW , Ana Maria CARRION , James Edgar CHASTAIN , Kirk Lee CLARK , Bijan Alexandre ETEMAD-GILBERTSON , Joy Gispati GHOSH , Shawn Michael HANKS , Nicole HAUBST , Ganesh Rajan IYER , Nina MOKER , Andrew Anh NGUYEN , Stephen Hendrick POOR , Yubin QIU , Nalini Velamur RANGASWAMY , Michael STEFANIDAKIS , Engin TOKSOZ , Michael Zbigniew TWAROG
Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
-
公开(公告)号：US20240011030A1
公开(公告)日：2024-01-11
申请号：US18020329
申请日：2021-08-09
Applicant: Novartis AG
Inventor： Yi BAO , Qian HUANG , Joshua SCHUSTAK , Michael Zbigniew TWAROG
IPC: C12N15/113 , C12N15/86 , C12N9/22 , A61K31/407 , A61K9/00
CPC classification number: C12N15/113 , C12N15/86 , C12N9/22 , A61K31/407 , A61K9/0048 , C12N2310/20 , C12N2310/14 , C12N2740/15043
Abstract: Methods for treating or improving a retinal degenerative disease or condition in a subject in need thereof are provided. In some embodiments described herein, the methods comprise administering to the subject a therapeutically effective amount of a retinoic acid-inducible gene I (RIG-I) inhibitor.
-
公开(公告)号：US20220025032A1
公开(公告)日：2022-01-27
申请号：US17375860
申请日：2021-07-14
Applicant: NOVARTIS AG
Inventor： Chad Eric BIGELOW , Ana Maria CARRION , James Edgar CHASTAIN , Kirk Lee CLARK , Bijan Alexandre ETEMAD-GILBERTSON , Joy Gispati GHOSH , Shawn Michael HANKS , Nicole HAUBST , Ganesh Rajan IYER , Nina MOKER , Andrew Anh NGUYEN , Stephen Hendrick POOR , Yubin QIU , Nalini Velamur RANGASWAMY , Michael STEFANIDAKIS , Engin TOKSOZ , Michael Zbigniew TWAROG
Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
-
公开(公告)号：US20220348646A1
公开(公告)日：2022-11-03
申请号：US17809943
申请日：2022-06-30
Applicant: NOVARTIS AG
Inventor： Chad Eric BIGELOW , Ana Maria CARRION , James Edgar CHASTAIN , Kirk Lee CLARK , Bijan Alexandre ETEMAD-GILBERTSON , Joy Gispati GHOSH , Shawn Michael HANKS , Nicole HAUBST , Ganesh Rajan IYER , Nina MOKER , Andrew Anh NGUYEN , Stephen Hendrick POOR , Yubin QIU , Nalini Velamur RANGASWAMY , Michael STEFANIDAKIS , Engin TOKSOZ , Michael Zbigniew TWAROG
Abstract: The present disclosure provides anti-BTC antibodies, methods of producing said antibodies, pharmaceutical compositions comprising said antibodies, and methods of using said antibodies. The present disclosure also provides multi-specific binding molecules, e.g., bispecific antibodies, comprising a BTC binding moiety and an anti-VEGF binding moiety.
-
-
-
Search Results
4
records
(took 0.009 seconds)
